Validation of the Human Activity Profile Questionnaire in Patients after Allogeneic Hematopoietic Stem Cell Transplantation Philipp Yorck Herzberg, Pia.

Slides:

Advertisements

Similar presentations

A Simplified Procedure for Hematopoietic Stem Cell Amplification Using a Serum-Free, Feeder Cell-Free Culture System Ian M. Rogers, Nobuko Yamanaka, Robert.

Advertisements

Steven Joffe, Michelle M. Mello, E. Francis Cook, Stephanie J. Lee

Galactomannan Antigen Enzyme-Linked Immunosorbent Assay for Diagnosis of Invasive Aspergillosis after Hematopoietic Stem Cell Transplantation Patrick.

Challenges around Access to and Cost of Life-Saving Medications after Allogeneic Hematopoietic Cell Transplantation for Medicare Patients Stephanie Farnia,

Stephanie J. Lee, Loretta A. Williams

Norovirus Infection in Pediatric Hematopoietic Stem Cell Transplantation Recipients: Incidence, Risk Factors, and Outcome Joseph Delano F. Robles, Daniel.

Current Practice in Diagnosis and Treatment of Acute Graft-versus-Host Disease: Results from a Survey among German-Austrian-Swiss Hematopoietic Stem Cell.

Admission of Hematopoietic Cell Transplantation Patients to the Intensive Care Unit at the Pontificia Universidad Católica de Chile Hospital Karen Escobar,

How to Treat MDS without Stem Cell Transplantation

The Effect of Statin Use at the Time of Autologous Transplant on Response and Survival in Multiple Myeloma Mehdi Hamadani, Erinn Hade, Don M. Benson,

Steven Joffe, Michelle M. Mello, E. Francis Cook, Stephanie J. Lee

Vaccination of Children following Allogeneic Stem Cell Transplantation

Toll-Like Receptor Polymorphisms in Allogeneic Hematopoietic Cell Transplantation Brian Kornblit, Christian Enevold, Tao Wang, Stephen Spellman, Mike.

Prognostic Factors of Chronic Graft-versus-Host Disease Following Allogeneic Peripheral Blood Stem Cell Transplantation: The National Institutes Health.

Peter Hurley, Suma Konety, Qing Cao, Daniel Weisdorf, Anne Blaes

Allogeneic Stem Cell Transplantation in Myelofibrosis

Impact of Donor Characteristics and HLA Matching on Survival of Chinese Patients with Hematologic Malignancies Undergoing Unrelated Hematopoietic Stem.

Late Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation Aazim K. Omer, Daniel J. Weisdorf, Aleksandr Lazaryan,

Hematopoietic Stem Cell Transplantation after Reduced Intensity Conditioning in Acute Myelogenous Leukemia Patients Older Than 40 Years Cynthia Huisman,

Oral Manifestations Compatible with Chronic Graft-versus-Host Disease in Patients with Fanconi Anemia Laura Grein Cavalcanti, Renata L. Fuentes Araújo,

Sabina Kersting, Leo F. Verdonck

Assessment of the Hematopoietic Cell Transplantation Comorbidity Index in Non- Hodgkin Lymphoma Patients Receiving Reduced-Intensity Allogeneic Hematopoietic.

Vascular Endothelial Growth Factor and Activin-A Serum Levels Following Allogeneic Hematopoietic Stem Cell Transplantation David Nachbaur, Petra Schumacher,

Carbon Monoxide Diffusion Capacity: How Low Can You Go for Hematopoietic Cell Transplantation Eligibility? Jason W. Chien, Keith M. Sullivan Biology.

Betty T. Tran, Abigail Halperin, Jason W. Chien

Outcome and Prognostic Factors for Patients Who Relapse after Allogeneic Hematopoietic Stem Cell Transplantation Gita Thanarajasingam, Haesook T. Kim,

Decision Analysis of Peripheral Blood versus Bone Marrow Hematopoietic Stem Cells for Allogeneic Hematopoietic Cell Transplantation Joseph Pidala, Claudio.

Stephanie J. Lee, Loretta A. Williams

Increased Risk of Bone Loss without Fracture Risk in Long-Term Survivors after Allogeneic Stem Cell Transplantation Bipin N. Savani, Theresa Donohue,

Pretransplantation Supportive and Palliative Care Consultation for High-Risk Hematopoietic Cell Transplantation Patients Elizabeth T. Loggers, Thomas.

Cytomegalovirus Infection after Allogeneic Transplantation: Comparison of Cord Blood with Peripheral Blood and Marrow Graft Sources Christopher M. Walker,

Evaluation of Hematopoietic Stem Cell Mobilization Rates with Early Plerixafor Administration for Adult Stem Cell Transplantation Jessica T. Stover,

New Light Chain Amyloid Response Criteria Help Risk Stratification of Patients by Day 100 after Autologous Hematopoietic Cell Transplantation Anita D'Souza,

Risk Factors and Outcome of Chronic Graft-versus-Host Disease after Allogeneic Stem Cell Transplantation—Results from a Single-Center Observational Study

Time to Insurance Approval in Private and Public Payers Does Not Influence Survival in Patients Who Undergo Hematopoietic Cell Transplantation Vijaya.

Follicular Lymphoma: Prognostic Factors, Conventional Therapies, and Hematopoietic Cell Transplantation Laurie H. Sehn, Timothy S. Fenske, Ginna G. Laport

Oral Chronic Graft-versus-Host Disease Scoring Using the NIH Consensus Criteria Nathaniel S. Treister, Kristen Stevenson, MS, Haesook Kim, Sook-Bin Woo,

Improvement of Pulmonary Function with Imatinib Mesylate in Bronchiolitis Obliterans Following Allogeneic Hematopoietic Cell Transplantation Navneet.

Kasiani C. Myers, Stella M. Davies

Effect of Conditioning Regimen Intensity on Acute Myeloid Leukemia Outcomes after Umbilical Cord Blood Transplantation Betul Oran, John E. Wagner, Todd.

Allogeneic Hematopoietic Stem Cell Transplantation in Adult Acute Lymphocytic Leukemia: Impact of Donor Source on Survival Priya Kumar, Todd E. Defor,

Incidence, Predisposing Factors, and Outcome of Engraftment Syndrome in Pediatric Allogeneic Stem Cell Transplant Recipients Irene Schmid, Daniel Stachel,

Pharmacokinetic Evaluation of the Drug Interaction between Intravenous Itraconazole and Intravenous Tacrolimus or Intravenous Cyclosporin A in Allogeneic.

Iron Overload Manifesting as Apparent Exacerbation of Hepatic Graft-versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation Rammurti.

Sabina Kersting, Ronald J. Hené, Hein A. Koomans, Leo F. Verdonck

Shigeo Fuji, Hermann Einsele, Bipin N. Savani, Markus Kapp

Predonation Health-Related Quality of Life Scores Predict Time to Recovery in Hematopoietic Stem Cell Donors Annelies Billen, J. Alejandro Madrigal,

Allogeneic Stem Cell Transplantation for Aplastic Anemia

CD19+CD21low B Cells and CD4+CD45RA+CD31+ T Cells Correlate with First Diagnosis of Chronic Graft-versus-Host Disease Hildegard T. Greinix, Zoya Kuzmina,

Trajectories of Quality of Life after Hematopoietic Cell Transplantation: Secondary Analysis of Blood and Marrow Transplant Clinical Trials Network 0902.

Lung Function, Pulmonary Complications, and Mortality after Allogeneic Blood and Marrow Transplantation in Children Zühre Kaya, Daniel J. Weiner, Deniz.

Regression Models for Hazard Rates Versus Cumulative Incidence Probabilities in Hematopoietic Cell Transplantation Data Brent R. Logan, Mei-Jie Zhang,

ASBMT and CBMTG Release Choosing Wisely BMT Recommendations

Galactomannan Antigen Enzyme-Linked Immunosorbent Assay for Diagnosis of Invasive Aspergillosis after Hematopoietic Stem Cell Transplantation Patrick.

Recipient NOD2/CARD15 Variants: A Novel Independent Risk Factor for the Development of Bronchiolitis Obliterans after Allogeneic Stem Cell Transplantation

What is quality in a transplant program?

The Impact of Geographic Proximity to Transplant Center on Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation Karim E. Abou-Nassar, Haesook.

Content Validity of the Lee Chronic Graft-versus-Host Disease Symptom Scale as Assessed by Cognitive Interviews Emily C. Merkel, Sandra A. Mitchell,

Incidence and Risk Factors for Nontuberculous Mycobacterial Infection after Allogeneic Hematopoietic Cell Transplantation Jennifer Beswick, Elizabeth.

Unrelated Donor Hematopoietic Cell Transplantation: Factors Associated with a Better HLA Match Jason Dehn, Mukta Arora, Stephen Spellman, Michelle Setterholm,

Blood and Marrow Transplant Handbook

A Prognostic Score for Patients with Acute Leukemia or Myelodysplastic Syndromes Undergoing Allogeneic Stem Cell Transplantation Philippe Armand, Haesook.

Young Female Donors Do Not Increase the Risk of Graft-versus-Host Disease or Impact Overall Outcomes in Pediatric HLA-Matched Sibling Hematopoietic Stem.

Long-Term Morbidity and Mortality in Children with Chronic Graft-versus-Host Disease Classified by National Institutes of Health Consensus Criteria after.

Extramedullary Relapse of Acute Myelogenous Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: Better Prognosis Than Systemic Relapse

Mammen Chandy Biology of Blood and Marrow Transplantation

Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives Brenda M. Sandmaier, Stephen Mackinnon, Richard.

Clinical Outcome following Autologous and Allogeneic Blood and Marrow Transplantation for Relapsed Diffuse Large-Cell Non-Hodgkin’s Lymphoma Ivan Aksentijevich,

Mary Eapen Biology of Blood and Marrow Transplantation

Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?

Presentation transcript:

Validation of the Human Activity Profile Questionnaire in Patients after Allogeneic Hematopoietic Stem Cell Transplantation Philipp Yorck Herzberg, Pia Heussner, Friederike H.A. Mumm, Melanie Horak, Inken Hilgendorf, Stephanie von Harsdorf, Philipp Hemmati, Kathrin Rieger, Hildegard Greinix, Mathias Freund, Stephanie J. Lee, Ernst Holler, Daniel Wolff Biology of Blood and Marrow Transplantation Volume 16, Issue 12, Pages 1707-1717 (December 2010) DOI: 10.1016/j.bbmt.2010.05.018 Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 1 Influence of cGVHD severity according to the NIH Consensus (1 = mild, 2 = moderate, or 3 = severe) on the adjusted activity score (AAS). Biology of Blood and Marrow Transplantation 2010 16, 1707-1717DOI: (10.1016/j.bbmt.2010.05.018) Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 2 Influence of cGVHD severity according to the NIH Consensus (1 = mild, 2 = moderate, or 3 = severe) on the maximum activity score (MAS). Biology of Blood and Marrow Transplantation 2010 16, 1707-1717DOI: (10.1016/j.bbmt.2010.05.018) Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 3 Impact of change of cGVHD status on the MAS. Biology of Blood and Marrow Transplantation 2010 16, 1707-1717DOI: (10.1016/j.bbmt.2010.05.018) Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 4 Impact of change of cGVHD status on the AAS. Biology of Blood and Marrow Transplantation 2010 16, 1707-1717DOI: (10.1016/j.bbmt.2010.05.018) Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 5 Impact of change of cGVHD status on the physical functioning subscale of the SF36. Biology of Blood and Marrow Transplantation 2010 16, 1707-1717DOI: (10.1016/j.bbmt.2010.05.018) Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions

Figure 6 Impact of change of cGVHD status on the FACT-BMT total score. Figures 3-6. Mean MAS (Figure 3), AAS (Figure 4) of the HAP and Physical functioning subscale of the SF36 (Figure 5), and FACT-BMT total score (Figure 6) in correlation to the change of the overall severity of cGVHD (stable cGVHD [n = 52], improved cGVHD [n = 14], and progressive cGVHD [n = 8]) versus patients without cGVHD (n = 38). T1 refers to the time of inclusion, whereas T2 refers to evaluation 4-5 months after inclusion. Biology of Blood and Marrow Transplantation 2010 16, 1707-1717DOI: (10.1016/j.bbmt.2010.05.018) Copyright © 2010 American Society for Blood and Marrow Transplantation Terms and Conditions